Pharmacokinetic enhancement of the hepatitis C virus protease inhibitors VX-950 and SCH 503034 by co-dosing with ritonavir

Antiviral Chemistry and Chemotherapy

Volumn 18, Issue 3, 2007, Pages 163-167

  Kempf, Dale J ^a   Klein, Cheri ^a   Chen, Hui Ju ^a   Klein, Larry L ^a   Yeung, Clinton ^a   Randolph, John T ^a   Lau, Yau Y ^a   Chovan, Linda E ^a   Guan, Zhiwen ^a   Hernandez, Lisa ^a   Turner, Teresa M ^a   Dandliker, Peter J ^a   Marsh, Kennan C ^a  

^a ABBOTT LABORATORIES   (United States)

Author keywords

HCV protease inhibitor; PK boosting; Ritonavir; SCH 503034; VX 950

Indexed keywords

CYTOCHROME P450; LOPINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SCH 503034; UNCLASSIFIED DRUG; VX 950;

ARTICLE; DRUG BIOAVAILABILITY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INHIBITION; DRUG METABOLISM; DRUG POTENTIATION; HEPATITIS C VIRUS; HUMAN; LOW DRUG DOSE; NONHUMAN; PLASMA CLEARANCE; PLASMA HALF LIFE; PRIORITY JOURNAL;

EID: 34547490826     PISSN: 09563202     EISSN: None     Source Type: Journal    
DOI: 10.1177/095632020701800306     Document Type: Article

References (16)

1. Chu H-M, Herrmann E, Reesink HW, Forestier N, Weegink CJ, McNair L, Purdy S, Zeuzem S & Ette EI. (2005) Pharmacokinetics of VX-950, and its effect on hepatitis C viral dynamics (Abstract). Hepatology 42:694A.
2. Eron J, Yeni P, Gathe J, Estrada V., Dejesus E., Staszewski S, Lackey P, Katlama C, Young B, Yau L, Sutherland-Phillips D, Wannamaker P, Vavro C, Patel L, Yeo J & Shaefer M (2006) The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial. Lancet 368:476-482.
3. Hsu A, Granneman GR, Witt G, Locke C, Denissen J, Molla A, Valdes J, Smith J, Erdman K, Lyons N, Niu P, Decourt J P, Fourtillan JB, Garault J & Leonard JM (1997) Multiple-dose pharmacokinetics of ritonavir in human immunodeficiency virus-infected subjects. Antimicrobial Agents & Chemotherapy 41:898-905.
4. Hsu A, Wada R, Poland B, Sun E & Granneman GR (2004) Modeling and simulation of effects of adherence, pharmacokinetic, and pharmacodynamic characterisics in development of resistance to HIV regimens in treatment naive patients in Advanced Methods of Pharmacokinetic and Pharmacodynamic Systems Analysis, vol. 3. Edited by D D'Argenio D. Boston/Dordrecht/London: Kluwer Academic Publishers, pp. 211-220.
5. Kempf DJ, King MS, Bernstein B, Cernohous P, Bauer E, Moseley J, Gu K, Hsu A, Brun S & Sun E (2004) Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine. Journal of Infectious Diseases 189:51-60.
6. Kempf DJ, Marsh KC, Kumar G, Rodrigues AD, Denissen JF, McDonald E, Kukulka MJ, Hsu A, Granneman GR, Baroldi PA, Sun E, Pizzuti D, Plattner JJ, Norbeck DW & Leonard JM (1997) Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. Antimicrobial Agents & Chemotherapy 41:654-660.
7. King JR, Wynn H, Brundage R & Acosta EP (2004) Pharmacokinetic enhancement of protease inhibitor therapy. Clinical Pharmacokinetetics 43:291-310.
8. Lamarre D, Anderson PC, Bailey M, Beaulieu P, Bolger G, Bonneau P, Bos M, Cameron DR, Carrier M, Cordingley MG, Faucher AM, Goudreau N, Kawai, SH, Kukolj G, Lagace L, Laplante SR, Nares H, Poupart MA, Rancourt J, Sentjens RE, St George R, Simoneau B, Steinmann G, Thibeault D, Tsantrizos YS, Weldon SM, Yong CL & Llinas-Brunet M (2003) An NS3 protease inhibitor with antiviral effects in humans infected with hepatitis C virus. Nature 426:186-189.
9. Malcolm BA, Liu R, Lahser F, Agrawal S, Belanger B, Butiewicz N, Chase R, Gheyas F, Hart A, Hesk D, Ingravallo P, Jiang C, Kong, R, Lu J, Pichardo J, Prongay A, Skelton A, Tong X, Venkatraman S, Xia E, Girijavallabhan V & Njoroge FG (2006) SCH 503034, a mechanism-based inhibitor of hepatitis C virus NS3 protease, suppresses polyprotein maturation and enhances the antiviral activity of alpha interferon in replicon cells. Antimicrobial Agents & Chemotherapy 50:1013-1020.
10. Perni RB, Almquist SJ, Byrn RA, Chandorkar G, Chaturvedi PR, Courtney LF, Decker CJ, Dinehart K, Gates CA, Harbeson SL, Heiser A, Kalkeri G, Kolaczkowski E, Lin K, Luong YP, Rao BG, Taylor WP, Thomson JA, Tung RD, Wei Y, Kwong AD & Lin C (2006) Preclinical profile of VX-950, a potent, selective, and orally bioavailable inhibitor of hepatitis C virus NS3-4A serine protease. Antimicrobial Agents & Chemotherapy 50:899-909.
11. Sham HL, Kempf DJ, Molla A, Marsh KC, Kumar GN, Chen CM, Kati W, Srewart K, Lai R, Hsu A, Betebenner D, Korneyeva M, Vasavanonda S, McDonald E, Saldivar A, Wideburg N, Chen X, Niu P, Park C, Jayanti V, Grabowski B, Granneman GR, Sun E, Japour AJ, Leonard JM, Plattner JJ & Norbeck DW (1998) ABT-378, a highly potent inhibitor of the human immunodeficiency virus protease. Antimicrobial Agents & Chemotherapy 42:3218-3224.
12. Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S & Da Silva B (2005) Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir. Clinical Infectious Diseases 41:1186-1195.
13. Shulman N, Zolopa A, Havlir D, Hsu A, Renz C, Boiler S, Jiang P, Rode R, Gallant J, Race E, Kempf DJ & Sun E (2002) Virtual inhibitory quotient predicts response to ritonavir boosting of indinavir-based therapy in human immunodeficiency virus-infected patients with ongoing viremia. Antimicrobial Agents & Chemotherapy 46:3907-3916.
14. Sulkowski MS, Metha SH, Chaisson RE, Thomas DL & Moore RD (2004) Hepatotoxicity associated with protease inhibitor-based antiretroviral regimens with or without concurrent ritonavir. AIDS 18:2277-2284.
15. Venkatraman S, Bogen SL, Arasppan A, Bennett F, Chen K, Jao E, Liu YT, Lovey R, Hendrata S, Huang Y, Pan W, Parekh T, Pinto P, Popov V, Pike R, Ruan S, Santhanam B, Vibulbhan B, Wu W, Yang W, Kong J, Liang X, Wong J, Liu R, Butkiewicz N, Chase R, Hart A, Agrawal S, Ingravallo P, Pichardo J, Kong R, Baroudy B, Malcolm B, Guo Z, Prongay A, Madison V, Broske L, Cui X, Cheng KC, Hsieh Y, Brisson JM, Prelusky D, Korfmacher W, White R, Bogdanowich-Knipp S, Pavlovsky A, Bradley P, Saksena AK, Ganguly A, Piwinski J, Girijavallabhan V & Njoroge FG (2006) Discovery of (1R,5S)-N-[3-amino-1-(cyclobutylmethyl)-2, 3-dioxopropyl]-3-[2(S)-[[[(1,1-dimethylethyl)amino] carbonyl]amino]-3,3- dimethyl-l-oxobuty 1]- 6,6-dimethyl-3-azabicyclo[3.1.0]hexan-2(S)-carboxamide (SCH 503034), a selective, potent, orally bioavailable hepatitis C virus NS3 protease inhibitor: a potential therapeutic agent for the treatment of hepatitis C infection. Journal of Medicinal Chemistry 49:6074-6086.
16. Zeuzem S, Sarrazin C, Rouzier R, Tarral A, Forestier N, Gupta S, Deckman D, Fellows K, Hussain M, Cutler DL & Zhang J (2005) Anti-viral activity of SCH 503034, a HCV protease inhibitor, administered as monotherapy in Hepatitis C genotype-1 patients refractory to pegylated interferon (Abstract). Hepatology 42:233A